What is the latest medical insurance price of acotinib/acalabrutinib in 2025?

Acalabrutinib is a second-generation Bruton's tyrosine kinase (BTK) inhibitor that is widely used in B cell-related hematological tumors such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). Compared with the first-generation BTK inhibitors, acotinib is more selective and has a lower risk of cardiovascular and bleeding-related side effects while maintaining excellent efficacy, so it is suitable for long-term oral maintenance treatment. In clinical practice, its mechanism of action helps patients stabilize their disease and improve their quality of life by specifically inhibiting BTK activity, blocking B cell receptor signaling pathways, and inhibiting abnormal B cell proliferation and survival.

In China, acotinib has been officially launched and included in the scope of medical insurance reimbursement. Eligible patients can purchase the drug through medical insurance in hospitals. The common specifications of capsule preparations are 100 mg, 8 capsules and 7 plates. The price per box is about 20,000 yuan. The specific cost varies depending on the hospital, region and medical insurance policy. Although the price is relatively high, medical insurance coverage significantly reduces the patient's out-of-pocket expense, making long-term treatment economically feasible. Especially for patients with CLL/SLL and patients with mantle cell lymphoma who have received at least one prior therapy, acotinib provides an important targeted therapy option.

Clinically, doctors will develop a personalized medication plan based on the patient's previous treatment history, disease progression, and individual constitution. During long-term treatment, it is necessary to regularly monitor changes in hematological indicators, liver and kidney function, and blood pressure, as well as pay attention to cardiovascular status in order to timely adjust the dose and manage adverse reactions. For some patients, doctors may adjust the dose based on blood drug concentration and tolerance to optimize efficacy and reduce the risk of side effects.

The advantage of long-term use of acotinib is that it can continuously maintain the control of B-cell diseases, reduce the probability of recurrence, and improve the long-term survival and quality of life of patients. At the same time, the oral dosage form is convenient for patients to use in a home environment, reducing the burden of hospitalization and infusion.

Reference materials:https://www.calquence.com/